logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Is rheumatoid arthritis becoming a milder disease ? Or are we starting second-line therapy in patients with milder disease ?

    Article - En anglais

    The aim of the study was to see whether rheumatoid arthritis (RA) is becoming a milder disease.

    Information on the initial disease activity and patient function (modified Health Assessment Questionnaire-HAQ) was collected in all RA patients enrolled into studies of sulphasalazine since 1980 in two Glasgow teaching hospitals.

    Patients (352) were enrolled in trials in the decade 1980-1989, and were compared to 374 patients enrolled in 1990-1994.

    Patients recruited in the 1980s were significantly younger, but had a similar disease duration to the 1990s patients.

    The 1980s patients had more active disease as measured by erythrocyte sedimentation rate (61 vs 44, P<0.0001) and C-reactive protein (40 vs 26, P<0.0001), and significantly worse function (HAQ 2.3 vs 1.9, P<0.001).

    The response to sulphasalazine was very similar in the two cohorts, in terms of the percentage of patients remaining on therapy for 6 months, and the percentage improvement in measures of disease activity.

    Patients with milder disease were enrolled into the more recent trials of sulphasalazine.

    This may be because RA is becoming a milder disease, but other possible explanations are discussed.

    Mots-clés Pascal : Polyarthrite rhumatoïde, Homme, Gravité, Epidémiologie, Evaluation, Questionnaire, Fonction articulaire, Efficacité traitement, Chimiothérapie, Sulfasalazine, Antirhumatismal, Chronique, Sulfamides, Système ostéoarticulaire pathologie, Rhumatisme inflammatoire, Immunopathologie, Maladie autoimmune

    Mots-clés Pascal anglais : Rheumatoid arthritis, Human, Gravity, Epidemiology, Evaluation, Questionnaire, Articular function, Treatment efficiency, Chemotherapy, Sulfasalazine, Antirheumatic agent, Chronic, Sulfanilamide derivatives, Diseases of the osteoarticular system, Inflammatory joint disease, Immunopathology, Autoimmune disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0146797

    Code Inist : 002B15D. Création : 21/05/1997.